基因启发式预后评分系统(GIPSS)在骨髓纤维化患者中优于动态国际预后评分系统(DIPSS)
在266例分子注释的骨髓纤维化患者外部队列中,GIPSS模型显著区分四个风险组,中位OS分别为未达到、未达到、60.5和28.9个月。GIPSS与DIPSS不一致≥2个风险组的39例患者中,GIPSS上调为遗传高危者较DIPSS上调为临床高危者总生存有更差趋势(P=.08),无白血病生存显著更差(P=.04)。GIPSS是有效的疾病特异性预后系统,在两模型不一致的患者中优于DIPSS。
要点
- GIPSS模型在266例骨髓纤维化患者中显著区分低、中1、中2、高危四组,中位OS分别为未达到、未达到、60.5和28.9个月。
- GIPSS与DIPSS不一致≥2个风险组的39例患者中,GIPSS上调者较DIPSS上调者无白血病生存显著更差(P=.04)。
- GIPSS评为中2和高危且接受异基因移植的患者较未移植者总生存改善(P=.04)。
核心结论
- GIPSS是有效的疾病特异性预后系统,在两模型不一致的患者中优于DIPSS。
- 当前研究表明,该当代遗传模型对原发性和继发性骨髓纤维化表现同样良好。
研究设计与样本
- 外部队列研究,纳入266例分子注释的骨髓纤维化患者,评估GIPSS模型并与DIPSS比较。
主要发现
- GIPSS模型显著区分四个风险组(低、中1、中2、高危),中位OS分别为未达到、未达到、60.5和28.9个月。
- 高危患者无白血病生存显著更差(P < 0.0001)。
- 识别出预后不确定患者39例,其GIPSS与DIPSS风险组差异≥2组;其中DIPSS上调19例,GIPSS上调20例。
- GIPSS上调(遗传高危)患者较DIPSS上调(临床高危)患者总生存有更差趋势(P = .08),无白血病生存显著更差(P = .04)。
- GIPSS评为中2和高危且接受异基因移植的患者较未移植者总生存改善(P = .04)。
关键数值与推荐
- GIPSS四组中位OS:低危未达到,中1未达到,中2 60.5个月,高危28.9个月。
- GIPSS与DIPSS风险组差异≥2组的患者共39例,DIPSS上调19例,GIPSS上调20例。
- GIPSS上调 vs DIPSS上调:OS差异P = .08,LFS差异P = .04。
- GIPSS中2和高危患者接受异基因移植 vs 未移植:OS差异P = .04。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A genetically inspired prognostic scoring system (GIPSS) that stratifies primary myelofibrosis (PMF) patients by genetic variants alone was recently proposed. While non-inferior to the dynamic international prognostic scoring system (DIPSS), the lack of overlapping prognostic variables between the models leads to increased risk for disagreement between two valid prognostic models and presents a challenging clinical situation. In an external cohort of 266 molecularly annotated myelofibrosis (MF) patients, we demonstrated that the GIPSS model significantly differentiated between four risk groups (low, int-1, int-2, high) with median OS that was not reached, not reached, 60.5 and 28.9 months, respectively. High-risk patients had significantly inferior leukemia-free survival (LFS) (P < 0.0001). We identified a cohort of prognostically ambiguous patients (n = 39) in which GIPSS and DIPSS models differed by ≥2 risk groups. Among these patients, a similar proportion were up-staged by DIPSS (n = 19) and GIPSS (n = 20). Patients upstaged by GIPSS (genetically high-risk) had a trend toward inferior OS compared with patients upstaged by DIPSS (clinically high-risk) (P = .08) and significantly worse LFS (P = .04). Patients deemed intermediate-2 and high-risk by GIPSS who underwent allogeneic transplant had improved OS compared with those that did not (P = .04). GIPSS is a valid disease-specific prognostic system and outperforms DIPSS in patients where the two models disagree. Additionally, while GIPSS was developed for PMF; the current study shows, however, that the contemporary genetic model performs equally well for both primary and secondary myelofibrosis.
引用
- Kuykendall AT, Talati C, Padron E, et al. Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients. Am J Hematol. 2018. PMID: 30390311. doi:10.1002/ajh.25335
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。